Infliximab: An updated review of its use in Crohn's disease and rheumatoid arthritis

BioDrugs

Volumn 16, Issue 2, 2002, Pages 111-148

  Keating, Gillian M ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Crohn's disease; Infliximab; Pharmacodynamics; Pharmacokinetics; Rheumatoid arthritis; Therapeutic use; Tumour necrosis factor

Indexed keywords

CHEMOKINE; CHIMERIC ANTIBODY; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; LEFLUNOMIDE; MACROPHAGE MIGRATION INHIBITION FACTOR; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT ONSET STILL DISEASE; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG INFUSION; DRUG MECHANISM; DRUG MONITORING; DRUG RESPONSE; DRUG TOLERABILITY; DRUG USE; EMBASE; ENTEROCUTANEOUS FISTULA; HEALTH CARE UTILIZATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MEDLINE; MULTICENTER STUDY; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT;

EID: 0036096689     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200216020-00005     Document Type: Article

References (205)

1. Treatment of Crohn's disease with infliximab
2. New therapeutic approaches to the management of rheumatoid arthritis
3. Immunotherapy of Crohn's disease
4. Guidelines for the management of rheumatoid arthritis
5. TNFaα - A pivotal role in rheumatoid arthritis?
6. Anti-TNF α therapy of rheumatoid arthritis: What have we learned?
7. Anti-TNF strategies in Crohn's disease: Mechanisms, clinical effects, indications
8. Construction and initial characterization of a mouse-human chimeric anti- TNF antibody
9. Infliximab: A review of its use in Crohn's disease and rheumatoid arthritis
10. Infliximab: A review of its use in the management of rheumatoid arthritis
11. Cytokine inhibition in the treatment of rheumatic and inflammatory diseases
12. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
13. Chemokines and cytokines in inflammatory bowel disease and their application to disease treatment
14. Role of cytokines in rheumatoid arthritis
15. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis
16. Cytokine pathways and joint inflammation in rheumatoid arthritis
17. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases
18. Infliximab downregulates interferon-γ production in activated gut T-lymphocytes from patients with Crohn's disease
19. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions
20. Review article: The clinical role of anti-TNFα antibody treatment in Crohn's disease
21. Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4
22. Anti-TNF antibody CA2 induces apoptosis in CD3/CD28 stimulated Jurkat cells; a potent immunomodulatory mechanism
23. Transmembrane TNF-α, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease
24. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway
25. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis
26. In vivo blockade of tumor necrosis factor-α in patients with rheumatoid arthritis: Longterm effects after repeated infusion of chimeric monoclonal antibody cA2
27. Reduction in serum VEGF and sICAM-1 are associated with clinical response to anti-TNF therapy in patients with severe Crohn's disease
28. 99MTC-WBC-scintigraphy
29. Decreased production of chemokines in patients with Crohns disease after anti-TNF therapy
30. Angiogenesis as a therapeutic target in rheumatoid arthritis: Serum vascular endothelial growth factor is decreased by anti-TNFα therapy
31. A role for TNF-α and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease
32. Systemic anti-tumor necrosis factor α therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor α synthesis
33. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis
34. In vivo blockade of TNF-α by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis: Short tem cellular and molecular effects
35. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis
36. Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNFα antibody therapy
37. Treatment of Crohn's disease anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
38. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease
39. Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
40. Treatment with monoclonal antibody anti-tumor necrosis factor α antibody results in an accumulation of Thl CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis
41. Deactivation of vascular endothelium by monoclonal anti-rumor necrosis factor α antibody in rheumatoid arthritis
42. 2 in healthy humans and in active Crohn's disease
43. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-α (cA2) therapy
44. Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor α monoclonal antibody (cA2)
45. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis
46. Target effector role of vascular endothelium in the inflammatory response: Insights from the clinical trial of anti-TNFα antibody in rheumatoid arthritis
47. Chimeric anti-tumor necrosis factor-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy
48. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
49. Do infliximab and methotrexate act synergistically in the treatment of rheumatoid arthritis? Comment on the article by Maini et al
50. Do infliximab and methotrexate act synergistically in the treatment of rheumatoid arthritis?
51. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
52. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
53. Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: Current and future perspectives
54. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
55. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
56. Infliximab for the treatment of fistulas in patients with Crohn's disease
57. Treatment of Crohn's disease (CD): Response to Remicade(R) (infliximab) in the ACCENT I trial through week 54
58. Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-α for Crohn's disease in Japan: Evaluation by rapid turnover proteins, and radiologic and endoscopic findings
59. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease
60. Clinical efficacy of treatment with infliximab in a German multicenter, prospective, open-label trial in refractory Crohn's disease
61. Infliximab therapy for Crohn's disease fistulae: Number of infusions required for response and time to relapse
62. Inflixmab (anti-TNF-α antibody) in treatment of rectovaginal fistulas with Crohn's disease
63. Development of a Crohn's Disease Activity Index: National Cooperative Crohn's Disease Study
64. Development and validation of an endoscopic index of the severity for Crohn's disease: A prospective multicentre study
65. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index
66. Clinical experience with infliximab therapy in 100 patients with Crohn's disease
67. Efficacy and safety of infliximab in 221 Crohn's disease patients
68. Infliximab in Crohn's disease: First anniversary clinical experience
69. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: The first 100 patients
70. Infliximab in Danish Crohn's disease patients
71. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-α, in the treatment of Crohn's disease: Is its efficacy augmented by steroid-sparing immunosuppressive therapy?
72. Intravenous Remicade outpatient treatment of Crohn's disease: A personal experience
73. Treatment of Crohn's disease with infliximab - An initial community practice experience
74. Clinical use of Infliximab in Crohn's disease: The Edinburgh experience
75. A simple index of Crohn's-disease activity
76. A multicenter study of infliximab (anti-TNFα antibody) in the treatment of children with active Crohn's disease
77. Collaborative experience of open-label infliximab in refractory pediatric Crohn's disease
78. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease
79. Use of infliximab in the treatment of Crohn's disease in children and adolescents
80. Use of infliximab in pediatric patients with inflammatory bowel disease
81. Consistency of treatment benefit with infliximab in patients with moderate-to-severe active Crohn's disease
82. Mechanisms in failure of infliximab for Crohn's disease
83. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease
84. Response to infliximab is decreased in the presence of intestinal strictures in patients with Crohn's disease
85. Duration of response following cessation of infliximab therapy for active or fistulizing Crohn's disease
86. Infliximab (Remicade) maintenance treatment strategy is superior to episodic treatment in patients with Crohn's disease
87. ACCENT I trial: Infliximab response rates over 30 weeks
88. Infliximab (Remicade) treatment allows Crohns disease to reduce or discontinue concomitant corticosteroid use
89. Three dose induction regimen of infliximab (Remicade) is superior to a single dose in patients with Crohns disease (CD)
90. Attenuation of response to multiple retreatment infliximab infusions for active Crohn's disease (CD): Potential factors that minimize decreased response
91. Does coadministration of immunosuppressive agents alter response to infliximab in Crohn's disease?
92. Consistent treatment benefit with infliximab in patients with fistulizing Crohn's disease
93. Pretreatment with 6-mercaptopurine/azathioprine prolongs clinical response time in Crohn's disease (CD) patients with fistulizing disease (FD) treated with inflixmab
94. Management of Crohn's disease in adults
95. Improvement of pyoderma gangrenosum after infliximab treatment for fistulizing Crohn's disease
96. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor α monoclonal antibody
97. Treatment with anti-TNF alpha (Remicade) for pyoderma gangrenosum in Crohn's colitis - Case report
98. Crohn's disease with spondyloarthropathy: Effect of TNF-α blockade (infliximab) on articular symptoms
99. Crohn's disease arthritis treated with infliximab: An open trial in four patients
100. Treatment of severe esophageal Crohn's disease with infliximab
101. Successful treatment of refractory esophageal Crohn's disease with infliximab
102. Infliximab for the treatment of orofacial Crohn's disease
103. Extensive dermatologic complications of Crohn's disease: Response to Remicade
104. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study
105. Infliximab for patients with refractory ulcerative colitis
106. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis
107. Infliximab, novel therapy for pediatric ulcerative colitis
108. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factorα (cA2) versus placebo in rheumatoid arthritis
109. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factorα
110. Repeated therapy with monoclonal antibody to tumour necrosis factorα (cA2) in patients with rheumatoid arthritis
111. Infliximab and methotrexate in the treatment of rheumatoid arthritis
112. Safety and efficacy of infliximab in 263 patients with active rheumatoid arthritis (RA) despite methotrexate therapy: A German open label trial
113. Short-term treatment with monoclonal antitumor necrosis factor-α antibody in refractory long-standing rheumatoid arthritis
114. Infliximab (Remicade®) ameliorates clinical signs and symptoms of rheumatoid arthritis within 48 hours: Results of the PROMPT study
115. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis
116. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo
117. Plain X-rays in rheumatoid arthritis: Overview of scoring methods, their reliability and applicability
118. The safety and efficacy of leflunomide (LEF) in combination with infliximab (INF) in rheumatoid arthritis (RA)
119. Effiacy and safety of Remicade(Rm) (infliximab) plus Arava(TM) (leflunomide) in rheumatoid arthritis (RA)
120. 102-Wk clinical and radiologic results from the ATTRACT trial: A 2 year, randomized, controlled, phase 3 trial of infliximab (Remicade®) in pts with active RA despite MTX
121. Radiological progression rate at baseline predicts treatment differences: Results from the ATTRACT trial
122. Infliximab plus methotrexate prevents structural damage, reduces signs and symptoms and improves disability in patients with active early rheumatoid arthritis
123. Subgroup analyses show consistent clinical benefit in a 30-week double blind trial (ATTRACT) with an anti-TNFα monoklonal antibody, infliximab, in rheumatoid arthritis patients on methotrexate
124. Consistent improvement in radiographic joint damage in patients with active rheumatoid arthritis treated with infliximab along with methotrexate
125. Infliximab vs. etanercept in the treatment of severe juvenile chronic arthritis
126. Evaluation of disease activity, disability and quality of life in patients with persistently active refractory juvenile idiopathic (chronic) arthritis treated with monoclonal anti-tumor necrosis factor-α antibody (infliximab)
127. Treatment of psoriatic arthritis with infliximab in a small office-based rheumatology practice
128. Successful treatment of psoriatic arthritis with infliximab in a MRI controlled study
129. Infliximab therapy in 15 patients with psoriatic arthritis
130. Quality of life improvement in patients with severe ankylosing spondylitis upon treatment with the anti-TNFα antibody infliximab in a placebo-controlled multicenter trial
131. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab
132. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab
133. Treatment of ankylosing spondylitis with infliximab
134. Efficacy of infliximab (Remicade) in the treatment of spondyloarthropathies, two case reports
135. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: First experiences
136. Infliximab in the treatment of adult Still's disease refractory to conventional therapy
137. Infliximab (Remicade) treatment results in rapid quality of life improvement in patients with Crohn's disease
138. Infliximab improves quality of life in Crohn's disease patients
139. Infliximab improves long-term quality of life and functional status in patients with rheumatoid arthritis
140. A new measure of health status for clinical trials in inflammatory bowel disease
141. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease
142. Measurement of patient outcome in arthritis
143. The MOS 36-item short-form health survery (SF-36)
144. Infliximab decreases resource utilization in patients with Crohn's disease
145. Analysis of the long-term costs, savings and effects generated by infliximab to normalize quality of life in patients with Crohn's disease
146. Infliximab: Outcomes and costs in refractory Crohn's disease
147. Cost-utility of initial medical management for Crohn's disease perianal fistulae
148. Estimating the cost-effectiveness of infliximab for Crohn's disease
149. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis
150. Cost effectiveness of infliximab in rheumatoid arthritis
151. Pharmacoeconomic analysis of the treatment of rheumatoid arthritis with Leflunomide in comparison with the combination of infliximab and methotrexate
152. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis
153. Long-term follow-up of patients treated with infliximab (anti-TNFα antibody) in clinical trials
154. Safety and tolerability of a rapid infusion of Remicade (infliximab) in the treatment of rheumatoid arthritis
155. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent
156. Delayed hypersensitivity to infliximab (Remicaide®) re-infusion after a 2-4 year interval without treatment
157. Mortality associated with infliximab
158. Severe anaphylactic reaction to infliximab: Report of a case
159. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trials
160. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides
161. Outcome of pregnancy in women receiving Remicade® (infliximab) for the treatment of Crohn's disease or rheumatoid arthritis
162. Advances in the management of Crohn's disease: Economic and clinical potential of infliximab
163. An asessment of the annual and long-term direct costs of rheumatoid arthritis
164. The costs of rheumatoid arthritis: Absolute, incremental, and marginal estimates
165. Review article: The limitations of corticosteroid therapy in Crohn's disease
166. Steroid-dependent Crohn's disease
167. Infliximab for the treatment of Crohn's disease: Review and indications for clinical use in Canada
168. Infliximab (Remicade): The magic bullet for Crohn's disease?
169. Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003
170. Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of infliximab in Crohn's disease
171. Crohn's disease in children and adolescents: What are the treatment options?
172. Chronic inflammatory bowel disease in children: A complex problem in management
173. Clinical and economic review of disease-modifying antirheumatic drugs
174. Rational use of new and existing disease-modifying agents in rheumatoid arthritis
175. Rheumatoid arthritis: Pathogenesis and early recognition
176. Mortality in rheumatoid arthritis
177. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis
178. Consensus recommendations for the assessment and treatment of rheumatoid arthritis
179. Etanercept: A review of its use in rheumatoid arthritis
180. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
181. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
182. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
183. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial
184. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
185. WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis
186. Etanercept and infliximab for rheumatoid arthritis
187. Coverage inequalities of new therapies for rheumatoid arthritis in a managed care setting
188. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of Genant and Larsen scores
189. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
190. Guidelines for monitoring drug therapy in rheumatoid arthritis
191. Maintenance therapy in Crohn's disease
192. Transcending conventional therapies: The role of biologic and other novel therapies
193. Strategies targeting tumor necrosis factor in Crohn's disease
194. Anti-TNF therapy and malignancy - A critical review
195. Long term safety of infliximab